local_hospital

Hospital Universitario Virgen De Valme

Address
lock Available on a paid plan

Cardiovascular and Metabolic Research

At Hospital Universitario Virgen De Valme, this research area focuses on cardiovascular diseases and related metabolic disorders, including atherosclerotic cardiovascular disease, chronic heart failure, and dyslipidemia. The trials are mainly designed to test new treatment options and better ways to reduce major heart-related risks and complications.

  • Studying treatments for chronic heart failure with reduced ejection fraction and related outcomes
  • Evaluating approaches for atherosclerotic cardiovascular disease and prevention of major cardiovascular events
  • Assessing therapies aimed at improving LDL cholesterol control in dyslipidemia

This line of research supports better prevention and long-term management of common heart and lipid disorders in patients treated at the site.

Autoimmune and Inflammatory Disease Studies

A major focus at the Servicio de Medicina Interna is immune system diseases, especially systemic lupus erythematosus, idiopathic inflammatory myopathy, psoriatic arthritis, and axial spondyloarthritis. These trials are exploring new therapies to control inflammation, improve symptoms, and assess longer-term safety in chronic autoimmune conditions.

  • Research on systemic lupus erythematosus to improve disease control and symptom relief
  • Trials in idiopathic inflammatory myopathy and psoriatic arthritis evaluating safety and effectiveness
  • Studies in axial spondyloarthritis and related inflammatory disorders aimed at better symptom management

The site is contributing to the development of more targeted options for patients living with persistent autoimmune disease.

Oncology and Cancer Treatment Research

The site conducts extensive neoplasm research across several cancer types, including non-small cell lung cancer, small cell lung cancer, breast cancer, endometrial cancer, colorectal cancer, bladder cancer, and chronic lymphocytic leukemia. These studies are designed to test new anticancer strategies, compare treatment effectiveness, and improve survival outcomes.

  • Investigating new treatment options for lung cancer, including advanced and mutation-defined subtypes
  • Studying early breast cancer and recurrence prevention after initial treatment
  • Evaluating therapies for endometrial cancer, colorectal cancer, bladder cancer, and chronic lymphocytic leukemia

This cancer portfolio reflects a strong interest in both earlier-stage disease and advanced tumors, with a clear emphasis on improving patient outcomes.

Respiratory, Infectious, and Hospital-Based Studies

Research at Hospital Universitario Virgen De Valme also includes respiratory tract diseases and virus diseases, with studies in COVID-19 and lung cancer-related respiratory conditions. These trials often aim to understand treatment benefit in hospitalized patients, reduce disease progression, and improve care during acute illness.

  • Clinical studies in COVID-19 focused on hospitalized patients with moderate to severe disease
  • Trials in respiratory cancers assessing new treatment combinations and survival outcomes
  • Hospital-based research aimed at improving outcomes in acute infectious and respiratory conditions

This area highlights the site's role in both pandemic-related research and complex respiratory disease management.

Digestive, Skin, and Other Specialized Clinical Research

The remaining studies cover a broad mix of digestive system diseases, skin and connective tissue diseases, and selected reproductive and urinary physiological phenomena. Key topics include ulcerative colitis, fertility-related research, and additional inflammatory conditions, with the goal of improving symptom control, treatment response, and patient quality of life.

  • Research in ulcerative colitis aimed at improving disease control in inflammatory bowel disease
  • Studies on male factor infertility exploring options to support conception
  • Additional work in skin and connective tissue and other less specific clinical areas

Together, these trials show a diverse internal medicine research program that extends beyond the major disease groups into other important clinical needs.

Site Overview

assignment
159
connected trials
corporate_fare
74
sponsors
science
311
IMPs

Activity Indicator

Last 6 months

13
Trials started
-7% vs previous period.
14
Trials started 6–12 months ago
159
Total trials linked
Highly Active
trending_downDeclining-7%
3
3
1
2
3
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 2 of 20 therapeutic areas and 15 of 311 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 306 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
60
Sponsors (total)
74
Active sponsors
40

Sponsor Network

Top 40 by active trials.

lock +39 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +31 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 567 other sites in Spain

description
Trial volume
159
Outperforms 93% of sites
public
Therapeutic diversity
20areas
Outperforms 92% of sites
groups
Sponsor diversity
74sponsors
Outperforms 92% of sites

Therapeutic Area Benchmark — Spain

Select a therapeutic area to compare against other sites in Spain.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Spain

Market Share

Country: Spain

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Hospital Universitario Virgen De Valme

lock Showing 1 of 159 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Comparative Study of ABP 234 and Pembrolizumab in Patients with Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerAmgen Inc.Phase IRecruitingOct 2024

IMP list

lock Showing 1 of 311 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Pembrolizumab22Unknown2015-11-062026-06-01

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.